

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
	<p>No equalities issues raised at scoping.</p> <p>The company noted that increased access to targeted therapies, including zanidatamab if recommended, has the potential to reduce health inequalities since there is a higher incidence of biliary tract cancer and poorer treatment outcomes in socio-economically deprived populations in England.</p>
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
	N/A
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
	N/A
4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

Technology Appraisals: Scoping

Equality impact assessment for the proposed single technology appraisal of Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

Issue date: May 2025

to the matrix been made?
No

Approved by Associate Director (name): ...Lorna Dunning.....

Date: ...13/05/25....